News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AxoGen, Inc. (AXGN) To Exhibit Nerve Repair Portfolio At American Academy of Orthopaedic Surgeons 2014 Annual Meeting



3/12/2014 11:41:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALACHUA, Mar 12, 2014 (GLOBE NEWSWIRE via COMTEX) -- via PRWEB - AxoGen, Inc. AXGN -3.87% , the emerging leader of the $1.6 billion U.S. peripheral nerve repair market, is pleased to announce its participation at the American Academy of Orthopedic Surgeons (AAOS) 2014 Annual Meeting, March 11-15, 2014 at the Morial Convention Center in New Orleans, LA, Booth 5818.

"Increasing demand for nerve repair product options from orthopedic surgeons makes AAOS an ideal meeting to present the AxoGen portfolio of products," commented Jill Schiaparelli, Senior Vice President, Business Strategy & Marketing for AxoGen. "Surgeons who visit our booth will have an opportunity to handle and learn more about our full suite of products: Avance(R) Nerve Graft, AxoGuard(R) Nerve Connector and AxoGuard(R) Nerve Protector."

The AAOS Annual Meeting draws thousands of orthopedic surgeons and is the largest orthopedic meeting in the world, featuring presentations of scientific papers, scientific poster and technical exhibits, instructional courses, educational symposia, and company exhibits.

About AxoGen, Inc.

AxoGen AXGN -3.87% is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance(R) Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard(R) Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard(R) Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance(R) Nerve Graft is processed in the United States by AxoGen. AxoGuard(R) Nerve Connector and AxoGuard(R) Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary.

Cautionary Statements Concerning Forward-Looking Statements.

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2014 revenue estimate, product development, product potential, financial performance, sales growth, product adoption, market awareness of our

products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: AxoGen, Inc.

CONTACT: AxoGen, Inc.
Greg Freitag, CFO & General Counsel
InvestorRelations@AxoGenInc.com
+1 (612) 619-6324

Help employers find you! Check out all the jobs and post your resume

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES